OncoMatch/Clinical Trials/NCT03079323
Trial to Investigate the Benefit of Elective Para-Aortic Radiotherapy (PART) for pN1 Prostate Cancer
Is NCT03079323 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for prostate cancer.
Prospective non-randomized phase 2 trial to study the efficacy of additional elective para-aortic RT (PART) in pN1 patients compared to those who were historically treated with adjuvant whole pelvic radiotherapy (WPRT) alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage PN1
Excluded: Stage CM1A, CM1B, CM1C
Presence of pN1 disease after ePLND (criteria defined in the protocol); Presence of cM1a, cM1b or cM1c disease [excluded]
Demographics
Prior therapy
Cannot have received: radiotherapy
Exception: if makes WPRT and/or PART impossible
Former radiotherapy making WPRT and/or PART impossible
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03079323 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage PN1 is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages